Pharmaceutical

INCB-57643 by Incyte for Myelofibrosis: Likelihood of Approval

INCB-57643 is under clinical development by Incyte and currently in Phase II for Myelofibrosis.

Feb 8, 2024 - 18:00
INCB-57643 is under clinical development by Incyte and currently in Phase II for Myelofibrosis.
Read the original article

Tags:

Previous Article

STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts ...

Next Article

AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Merz strengthens its global footprint with botulinum approval in Australian market

Merz strengthens its global footprint with botulinum ap...

Nov 22, 2023

STAT+: FDA advisory panel votes in favor of Abbott’s new heart device

STAT+: FDA advisory panel votes in favor of Abbott’s ne...

Feb 13, 2024

Sage lays off 55% of R&D workforce and refocuses pipeline

Sage lays off 55% of R&D workforce and refocuses pipeline

Oct 18, 2024